
==== Front
Int J Oncol
Int J Oncol
IJO
International Journal of Oncology
1019-6439
1791-2423
D.A. Spandidos

39239759
10.3892/ijo.2024.5687
ijo-65-04-05687
Review
NLRC4, inflammation and colorectal cancer (Review)
Tong Guojun 12
Shen Yan 3
Li Hui 3
Qian Hai 3
Tan Zhenhua 3
1 Department of Colorectal Surgery, Huzhou Central Hospital, The Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang 313003, P.R. China
2 Central Laboratory, Huzhou Central Hospital, The Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang 313003, P.R. China
3 Department of General Surgery, Huzhou Central Hospital, The Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang 313003, P.R. China
Correspondence to: Mrs. Yan Shen, Department of General Surgery, Huzhou Central Hospital, The Affiliated Central Hospital of Huzhou University, 1558 Sanhuan North Road, Huzhou, Zhejiang 313003, P.R. China, E-mail: shenyan1160@126.com
10 2024
04 9 2024
04 9 2024
65 4 9909 7 2024
19 8 2024
Copyright: © 2024 Tong et al.
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Chronic inflammation is recognized as a major risk factor for cancer and is involved in every phase of the disease. Inflammasomes are central to the inflammatory response and play a crucial role in cancer development. The present review summarizes the role of Nod-like receptor C4 (NLRC4) in inflammation and colorectal cancer (CRC). Reviews of the literature were conducted using Web of Science, PubMed and CNKI, with search terms including 'NLRC4', 'colorectal cancer', 'auto-inflammatory diseases' and 'prognosis'. Variants of NLRC4 can cause recessive immune dysregulation and autoinflammation or lead to ulcerative colitis as a heterozygous risk factor. Additionally, genetic mutations in inflammasome components may increase susceptibility to cancer. NLRC4 is considered a tumor suppressor in CRC. The role of NLRC4 in CRC signaling pathways is currently understood to involve five key aspects (caspase 1, NLRP3/IL-8, IL-1β/IL-1, NAIP and p53). The mechanisms by which NLRC4 is involved in CRC are considered to be threefold (through pyroptosis, apoptosis, necroptosis and PANoptosis; regulating the immune response; and protecting intestinal epithelial cells to prevent CRC). However, the impact of NLRC4 mutations on CRC remains unclear. In conclusion, NLRC4 is a significant inflammasome that protects against CRC through various signaling pathways and mechanisms. The association between NLRC4 mutations and CRC warrants further investigation.

Key words

Nod-like receptor C4
colorectal cancer
prognosis
mechanism of action
signaling pathway
Science and Technology Project of Zhejiang Province2018C37090 This study was supported by the Science and Technology Project of Zhejiang Province (grant no. 2018C37090).
==== Body
pmc1. Background

Nod-like receptor C4 (NLRC4), initially characterized by Poyet et al (1), is known for its role in promoting apoptosis. NLRC4 is now recognized for initiating an exponential cascade of adapter recruitment and caspase (CASP)1 autoproteolysis, a process termed inflammasome activation, resulting in the cleavage of inflammatory substrates such as pro-IL-1β, pro-IL-18 and gasdermin D (GSDMD), which are activated and inhibit the occurrence and development of numerous types of malignant tumor, including colorectal cancer (CRC) (2). Duncan and Canna (2) have examined the distinctive dual role of NLRC4 as both an initiator of inflammasome activation and an NLR protein. p53 activation, triggered by genotoxic stress and pro-inflammatory signals such as those from TNF, has been shown to increase NLRC4 levels (3,4). The first evidence that NLRC4 activation is modulated by specific ligands came from a study showing that murine macrophages deficient in NLRC4 cannot initiate CASP1 upon encountering Salmonella typhimurium (5). Although uncertainties remain about the specific kinases involved in the phosphorylation of NLRC4 and their functional significance, the accumulated functional insights suggest that these kinases are likely integral to the regulatory framework ensuring proper NLRC4 activation during infection (2).

Unlike other NLR proteins, comprehensive structural analyses of NLRC4 have significantly advanced the understanding of its activation triggers (2). NLRC4, as with other NLR family members, exhibits a tripartite structural arrangement: An N-terminal domain for homotypic interactions, a central domain for nucleotide binding and a series of C-terminal leucine-rich repeats (LRRs). The stability of the monomer is maintained through these interactions and the binding of ADP to the nucleotide binding site (6). Two studies (7,8) have shown that following co-expression of NLRC4 with NAIP2 and the type III secretion system (T3SS) needle protein, PrgJ, NAIP interacts with NLRC4 upon ligand binding, potentially forming disc-like structures composed of unfolded NLRC4 monomers. These monomers engage in extensive molecular interactions with adjacent NLRC4 molecules on opposing faces (2). NLRC4 is identified as a crucial component of the immune response against intestinal pathogens (2,9-11). A gene mutation in NLRC4 is suspected to be the first identified recessive mutation leading to the monogenic disorder, inflammatory bowel disease (IBD), characterized by autoinflammation and immune system irregularities triggered by environmental stimuli (12). Inflammation plays a key role in tumorigenesis leading to oncogenic mutations, tumor promotion and angiogenesis. Tumor promoting inflammation is driven by numerous factors, including the presence of the proinflammatory cytokines, interleukin (IL)-1β and IL-18. An important source of IL-1β and IL-18 secretion is via activation of the inflammasome. The inflammasome is a multiprotein complex that, upon activation, leads to the processing and secretion of IL-1β and IL-18, which is mediated by the cysteine protease, CASP1. Several inflammasomes, including NLR family pyrin domain containing 3 (NLRP3), NLRC4 and NLRP6, have been elucidated in tumorigenesis (12). Notably, inflammasomes play different roles in different types of cancer, showing the complexity of inflammation during tumorigenesis. Understanding these roles will help to identify new therapeutic targets and improve the treatment strategies of patients with cancer (12).

Inflammation plays a role in all stages of tumorigenesis. The key signaling pathway that leads to acute and chronic inflammation is via activation of the CASP1 inflammasome. Inflammasome complexes assemble upon activation of certain nucleotide-binding domains (NBDs), LRR proteins (NLRs), absent in melanoma 2 (AIM2)-like receptors or pyridines (13). The activation of inflammasome and IL-18 signaling pathways has a great protective effect in colitis-associated CRC, while excessive inflammation driven by inflammasome or IL-1 signaling pathways promotes breast cancer, fibrosarcoma, gastric cancer and lung metastasis (13). Inflammasomes are multimeric complexes consisting of NLRs, which react to a diverse array of endogenous (damage-associated molecular patterns) and exogenous (pathogen-associated molecular patterns) stimuli. Multiple lines of evidence suggest that in cancer, inflammasomes are positively correlated with features such as elevated IL-1β and IL-18 levels, activation of NF-κB signaling, increased mitochondrial oxidative stress and activation of the autophagy process (10,11,13,14). A number of NLRs, such as NLRP3 and NLRC4, have also been emphasized in carcinogenesis and are closely associated with activating inflammatory caspases (14). A particular genetic variant, Ala160Thr, exhibits pathogenic properties in vitro, amplifies NLRC4 signaling in response to stimuli (though with less potency than dominant mutations in NLRC4) and results in a slight increase in IL-18 in vivo. The variant form of NLRC4 (Ala160Thr) implicated in the recessive immune dysregulation was identified from intestinal epithelial cells (IECs) and colon tissue. Consequently, individuals carrying the NLRC4 (Ala160Thr) mutation are at a higher risk for developing ulcerative colitis (15). NLRC4 mutations can also cause autoinflammatory disease (16). Additionally, a previous study has found that NLRC4 expression is upregulated in tumor tissues compared with normal tissues and is associated with prognosis in lung adenocarcinoma (17). NLRC4 mediates the maturation and release of CASP1, further promoting the release of inflammatory factors, such as IL-1β and IL-18, and plays a critical role in various tumors. Depending on the type of cancer, NLRC4 may act as a tumor promoter or suppressor (18). For instance, NLRC4 promotes tumor progression in breast cancer (19), glioma (20) and liver cancer (21), but functions as a tumor suppressor in melanoma (22) and CRC (23). Another study demonstrated that high expression of NLRC4 was associated with a favorable prognosis in CRC (24). The present review examines the relationship between NLRC4 and inflammation, its function, signaling pathways and the mechanisms by which NLRC4 is involved in CRC.

2. Methods

Web of Science (https://www.webofscience.com/wos), PubMed (https://www.ncbi.nlm.nih.gov) and CNKI (https://kns.cnki.net) were used for the present literature review, with search terms including 'NLRC4', 'colorectal cancer', 'auto-inflammatory diseases' and 'prognosis'. A total of 599 articles related to NLRC4 were retrieved and imported into EndNote X7 (Clarivate). The inclusion criteria were as follows: NLRC4 associated with signaling pathways, mechanism IBD and CRC. The exclusion criteria were as follows: Missing the full text and not associated with CRC. According to these criteria, 299 articles were excluded and 300 full text articles were included. Among these articles, 98 addressed signaling pathways, 67 focused on the mechanisms of action, 158 discussed NLRC4 and IBD and 28 explored NLRC4 and the associations with CRC (Fig. 1). The present review did not involve statistical analysis. In terms of methodology, relevant literature were collected on the structure, function, mutations and the relationship of NLRC4 with inflammation and CRC. The present review is based on the possible signaling pathways, mechanisms of action and mutations related to the structure and inflammation, function and CRC as well as the action of CRC.

3. NLRC4 and inflammation

The NLR family comprises intracellular receptors that detect bacterial molecules, with NLRC4 as one of its members (25). These NLRs are proteins characterized by LRR motifs that enable them to recognize bacterial elements within the cytoplasm of eukaryotic cells. Upon detecting these bacterial elements, the inflammasome complex, which integrates certain NLRs, is triggered. This complex is crucial for activating CASP1, an enzyme that processes pro-inflammatory cytokines, such as IL-1β and IL-18, into their active forms (26,27). Initially, NLRC4 was primarily recognized as a sensor for flagellin in eukaryotic cells. However, research involving multiple pathogenic organisms, including Salmonella (18,28-30), Legionella (31-34), Shigella (25,35-38) and Pseudomonas (39-42), particularly at elevated pathogen concentrations, has shown that NLRC4 can initiate CASP1 activity regardless of the presence of bacterial flagellin (18,30). Additionally, emerging evidence suggests that NLRC4 can also limit bacterial infections in a CASP1-independent manner (43,44). These findings imply that NLRC4 may detect a broader spectrum of bacterial molecules and participate in multiple immune response pathways.

The structure of NLRC4 is illustrated in Fig. 2 (25). The NLRC4 structure comprises three distinct domains: The N-terminal caspase-activating and recruitment domain (CARD; residues 1-88), which interacts with the CARDs of both ASC and CASP1; the central NACHT domain (residues 163-457), which includes ATP/GTPase activity, a characteristic P-loop and a magnesium binding site, serving as a nucleotide-binding and oligomerization platform; and the C-terminal LRR domain (residues 656-1024), which includes at least 13 LRR units and detects upstream signals to trigger NLRC4 activation (1). The NLRC4 (Ala160Thr) variant can lead to recessive immune dysregulation and autoinflammation or contribute to the development of ulcerative colitis as a heterozygous risk factor, potentially related to an increased release of IL-18 compared with IL-1β (15,45,46).

4. NLRC4 function and CRC

NLRC4 functions as a sensor within the innate immune system. A 2004 study demonstrated that bone marrow-derived macrophages (BMDMs) from NLRC4-deficient mice were unable to initiate CASP1 activation, resulting in a failure in pyroptosis when challenged with S. Typhimurium (5). Various pathogens possess virulence factors similar to flagellin, which are crucial for activating the NLRC4 inflammasome. These include Pseudomonas aeruginosa (Pscl), Shigella flexneri (Mxil), Escherichia coli (EprJ and Escl), Burkholderia pseudomallei (BsaK) and S. Typhimurium (PrgJ) (47). Notably, the NLRC4 inflammasome can also be activated in the absence of flagellin during certain bacterial infections (48). Thus, NLRC4 is a key modulator of the innate immune response, capable of recognizing a range of bacterial virulence factors (18). The apoptosis inhibitory proteins of the NLR family, known as NAIPs, act as essential sensors for NLRC4 inflammasome activation. The murine genome encodes seven distinct NAIPs, while the human genome contains only one variant, hNAIP (49). Specifically, NAIP5 and NAIP6 have been shown to activate NLRC4 in response to bacterial flagellin (50). NAIP2, similar to NAIP5, serves as a receptor for the inflammasome, recognizing T3SS rod proteins such as BsaK from B. pseudomallei and PrgJ from S. Typhimurium (33). Furthermore, hNAIP can induce NLRC4 inflammasome activation in response to both flagellin and T3SS components (51-53). During bacterial invasion, the transcriptional regulation of NLRC4 and NAIPs is mediated by interferon regulatory factor 8 (IRF8) (42).

Functional redundancies between NLRP3 and NLRC4 can enhance host defense. Research indicates that mice with a dual deficiency in NLRC4 and NLRP3 due to knockout exhibit increased susceptibility to S. Typhimurium, with significantly higher bacterial loads in the mesenteric lymph nodes, liver and spleen compared with the healthy controls (54). Similarly, Citrobacter rodentium, another intestinal pathogen, can induce heightened pathology and increased susceptibility in mice lacking CASP1, NLRC4 and NLRP3, suggesting that NLRC4 is crucial for the defense against C. rodentium (55). In addition to its role in hematopoietic immune cell lineages during infection, NLRC4 is also activated in non-hematopoietic cell populations, notably within IECs (2). NLRC4 provides protection against certain pathogens, including Salmonella (28,30), Citrobacter (11,56) and Legionella (33,57). However, its activation can also be detrimental, potentially causing an excessive inflammatory response during certain infections, such as those by Helicobacter (18).

NLRC4 is a key factor in the pathogenesis of autoinflammatory diseases. While NLRC4 activation is crucial for initiating immune reactions and promoting inflammation in response to bacterial invasion, excessive activation can lead to unnecessary cellular death and cytokine release. Therefore, mutations causing NLRC4 overactivation are likely to be detrimental, potentially resulting in autoinflammatory diseases. Such genetic mutations can lead to continuous CASP1 activation and increased production of IL-1β and IL-18 in macrophages derived from patients expressing mutated NLRC4 (58). A distinct de novo gain-of-function (GOF) mutation in NLRC4, resulting in a p.Val341Ala amino acid substitution within the helical domain 1, leads to inflammasome activation and is associated with conditions such as near-fatal or fatal episodes of autoinflammation, periodic fever and neonatal-onset enterocolitis (15,59). Mice expressing this NLRC4 mutation exhibit severe cold-induced exanthema, splenomegaly, increased neutrophil infiltration, arthritis and dermatitis. In patients, this mutation typically results in inflammatory arthritis, skin erythema and recurrent fever (60,61). Given the significant role of NLRC4-associated cytokine signaling in disease development, therapeutic interventions targeting these pathways have been explored. Previous research has suggested that a combined therapeutic approach using rapamycin and anakinra may benefit patients with NLRC4 mutations (62).

The functions of NLRC4 in various forms of programmed cell death, including PANoptosis, necroptosis, apoptosis and pyroptosis, have been extensively studied. During infection, activating specific programmed cell death pathways is essential for eliminating invading pathogens from the host. Necroptosis and pyroptosis are typically characterized by their lytic nature and ability to elicit an immune response, whereas apoptosis was traditionally considered immunologically silent (2). However, one previous study has suggested that apoptosis may not always be silent (63). Emerging research has demonstrated that some infectious pathogens and non-microbial stressors can induce an inflammatory form of cell death known as PANoptosis (64). PANoptosis is a distinct and physiologically relevant pathway triggered by specific stimuli and regulated by the PANoptosome, a coordinating structure that facilitates the simultaneous activation of key components associated with necroptosis, apoptosis and pyroptosis (65-74). The involvement of NLRC4 in pyroptosis has been linked to retinal ganglion cell death and has provided new insights into the pyroptosis of microglia. This finding highlights potential therapeutic approaches for mitigating irreversible vision loss caused by glaucoma by targeting pyroptosis (75). Apoptosis is a programmed cell death process that enables the systematic and effective removal of damaged cells resulting from development or DNA damage. Apoptosis can be initiated by external signals, such as ligands binding to death receptors on the cell surface, or by internal factors such as genotoxic stress (76). The relationship between apoptosis and NLRC4 has been well established, with poly (ADP-ribose) polymerase 1 cleavage by CASPs serving as a definitive indicator of apoptosis (76). Necroptosis, a regulated form of necrotic cell death, is also crucial for the organism's defense against certain pathogens (77). During Salmonella infection, a recent study observed activation of mixed lineage kinase domain-like pseudokinase (necroptosis), CASP8, CASP7 and CASP3 (apoptosis), as well as CASP1 and GSDMD (pyroptosis) (62).

During various phases of cancer progression, including metastasis, angiogenesis, proliferation and immunosuppression, aberrant activation of the inflammasome plays a crucial role. Conversely, inflammasome activation can maintain the intestinal barrier and initiate tumor suppression, highlighting its complex role in tumorigenesis (78). Animal experiments involving deficiencies in key inflammasome factors such as NLRC4, Nlrp3, CASP1 and PYCARD have identified the pivotal role of NLR inflammasomes in the pathogenesis of colitis-associated cancer (CAC) (79-81). No significant differences in CAC disease outcomes or pathology were observed when comparing NLRC4−/− animals with controls (wild-type animals) (82). Additionally, another study found that treating NLRC4−/− mice with dextran sulfate sodium (DSS) and azoxymethane (AOM), which induce DNA damage, resulted in increased colonic epithelial cell proliferation, reduced apoptosis and larger tumor volumes (23). Additionally, NLRC4-deficient mice exhibited increased sensitivity to colitis induced by DSS compared with wild-type mice (82). Chemokines and cytokines play a crucial role in eliminating cancer cells, and NLRC4 activation is essential for the synthesis of these molecules in tumor-associated macrophages. In the B16F10 melanoma mouse model, NLRC4 is indispensable for the generation of IFN-γ by CD8+ and CD4+ T cells (83). However, a previous investigation indicated that NLRC4 does not contribute to melanoma progression, as no difference in tumor incidence was observed between NLRC4-deficient mice and wild-type littermates (84,85). Inflammation is believed to influence several phases of tumorigenesis, contributing to the host's resistance to harmful microbial infections and maintaining tissue balance. Disruptions in this process could potentially trigger inflammatory disorders and malignancies (86). NLRC4 is a pivotal component of the inflammasome complex, and its dysregulation is closely associated with the development of CRC associated with colitis (82). The role of NLRC4 in carcinogenesis varies by malignancy; it can act as either a suppressor or promoter (24). NLRC4 acts as a suppressor in CRC (23). Peng et al (24) found that high NLRC4 expression was associated with a favorable prognosis in CRC. However, it was not determined whether NLRC4 was an independent prognostic factor for CRC. Therefore, further investigation is needed to clarify this. The function of NLRC4 is summarized in Table I.

5. Possible signaling pathway of NLRC4 in CRC

Mutations in genes encoding inflammasome components often result in increased susceptibility to autoinflammatory diseases, infections or cancer in humans (83). NLRC4 may protect against CRC through the CASP1 signaling pathway (87). It is noteworthy that deficiencies in CASP1 and ASC render mice vulnerable to DSS-induced colitis and associated CRC (13,79-81,83,88), demonstrating that inflammasomes have a protective function in a CRC inflammatory model. NLRC4 may also protect against CRC through the NLRP3/IL-8 signaling pathway (83) (Fig. 3). NLRC4 and NLRP3 are two different inflammasomes with different expression levels that typically change consistently (75,89-91), although the precise mechanism remains unclear. One possibility is that inflammasome sensors such as NLRP3 facilitate the release of IL-18, an immune signaling protein that aids in restoring the epithelial barrier against injury. This function could explain how IL-18 exerts a protective effect against CRC associated with colitis (13,92-99).

Additionally, NLRC4 may play an anticancer role (suppressing transplantable tumors) through the IL-1β/IL-1 receptor signaling axis in dendritic cells (100). This pathway may stimulate an effective CD8+ T-cell response toward transplantable tumor cells (83) (Fig. 3). NLRC4 could potentially inhibit CRC implantation through this signaling pathway, although no literature currently shows that NLRC4 directly kills CRC cells via this axis.

NLRC4 may inhibit CRC via the NAIP signaling pathway (83) (Fig. 3). Mouse NAIP1-6 proteins, integral to the NLRC4 inflammasome, have been associated with a protective effect against CRC induced by AOM-DSS (101). The specific role of NLRC4 in the AOM-DSS tumorigenesis model remains unclear; one study suggests that NLRC4 may impede colorectal tumor development by inhibiting cell proliferation and promoting apoptosis (23). However, contrasting findings from another study did not attribute a significant role to NLRC4 (79). Additionally, NLRC4 can enhance inflammatory signaling in macrophages, independent of its role in inflammasome formation, and it increases IFN-γ production in CD8+ and CD4+ T cells, thereby suppressing melanoma tumor progression in a murine model (22).

NLRC4 may also protect against CRC via the p53 signaling pathway (87). As a tumor suppressor, p53 plays an important role in regulating the cell cycle, DNA repair, apoptosis and metabolic pathways. Research shows that 60% of patients with CRC have p53 gene mutations, which are associated with increased tumor invasiveness and drug resistance. Research has also confirmed that NLRC4 is considered to be involved in the downstream apoptotic signaling pathway of p53, exerting inhibitory functions on tumor formation. p53 can activate the expression of NLRC4 mRNA and is induced by upregulation of tyrosine phosphatase, TC-45, which activates p53 (87). NLRC4 also clears damaged epithelial cells through p53 mediated apoptosis, limiting their further abnormal proliferation and transformation into malignant tumors. Therefore, an NLRC4-induced increase in tumor cell apoptosis may be achieved by mediating p53 activation (14,102,103). Further experiments are required to elucidate p53 mediated apoptosis, limiting the further abnormal proliferation and transformation of tumors into malignant tumors. For example, the p53 pathway and NLRC4 in CRC can be further explored through in vivo experiments in mice or in vitro experiments on CRC cell lines. In clinical practice, the relationship between NLRC4 mutations in serum, CRC adjacent tissues and tumor tissues and the prognosis of patients with CRC via the p53 pathway can be used as a research objective (104-106).

Bacterial flagellin, a classic pathogen-associated molecular pattern, interacts with Toll-like receptor 5 and the NAIP5 receptor (integral to the NLRC4 inflammasome), stimulating immune responses in mammals. However, the role of flagellin receptors in lower animal species is less understood (107). NLRC4 inflammasome may induce colitis inflammation and CRC via p53 signaling pathway. p53 activation is instrumental in promoting apoptosis in coelomocytes (107). Numerous studies have shown that the p53 signaling pathway is closely related to tumor cell apoptosis, thereby inhibiting tumor development (108-115). However, one study indicated that NLRC4 is not associated with the p53 signaling pathway in protecting against colonic tumorigenesis (101). Elevated pyroptosis, an indicator of a 'hot' tumor environment characterized by CD8+ T cells and various T cell subtypes, is influenced by oncogenic pathways including PI3K/AKT/mTOR signaling, angiogenesis, IL-2/STAT5 signaling, IL-6/Janus kinase/STAT3 signaling, epithelial-mesenchymal transition, KRAS signaling, DNA repair and the p53 pathway (116). Therefore, we suggest that NLRC4 is involved in the p53 signaling pathway to inhibit tumor development. Mechanistically, NLRC4 is considered to play a significant role in this pathway in CRC. These potential signaling pathways are summarized in Table II.

6. Possible mechanism of NLRC4 in CRC

From the above, it can be inferred that NLRC4 suppresses and eliminates CRC cells through pyroptosis, apoptosis, necroptosis and PANoptosis. The assembly of the inflammasome complex triggers the activation of CASP1, which is responsible for the maturation of IL-1β and IL-18 into their active forms and the cleavage of GSDMD, thereby inducing pyroptosis, a type of inflammatory cell death (117,118). Components such as NAIP-NLRC4, NLRP6, NLRP9, AIM2 and Pyrin can assemble into inflammasomes, playing a role in modulating the host's immune and inflammatory responses (119,120). NLRC4 protects against CRC as a cytosolic sensor by regulating the immune response. NLRP6, NLRP7, NLRP9, NLRP12, the DNA sensor IFNγ-inducible protein 16 and the RNA sensor RIG-I have been associated with promoting CASP1 activation, though confirmation of their capacity to assemble into an inflammasome complex is still needed (121).

NLRC4 protects IECs to prevent CRC. IECs form a crucial barrier against pathogen invasion. The intestinal immune system's defense and its disease potential are significantly influenced by a coordinated IEC-specific response involving the CASP1 and CASP8 inflammasomes (10). Irak et al (122) suggested that serum levels of monocyte chemoattractant protein 2/chemokine (C-C motif) ligand 8 and NLRC4 could contribute to the development of Crohn's disease and play a protective role in maintaining intestinal homeostasis and mitigating inflammation. Another study indicated that the prompt and targeted elimination of infected enterocytes by the epithelium-autonomous NAIP/NLRC4 system is crucial to prevent an excessive TNF-induced inflammatory response that could otherwise damage the epithelial barrier (123). NAIPs protect against colonic tumors by facilitating the clearance of epithelial cells stimulated by carcinogens, likely independent of the NLRC4 inflammasome (101). The administration of AOM, a DNA-damaging substance, along with repeated DSS injections, induces CRC progression associated with colitis (124,125). In mice, oxazolone, a haptenating agent, can also trigger hemorrhagic colonic inflammation and severe submucosal edema, in addition to DSS (126). Although NLRC4 does not contribute to the rapid genetic reconfiguration of the intestine in response to flagellin, its inflammasome activation generates IL-1β and IL-18, which protect mice from both mucosal and systemic inflammation (82). In summary, NLRC4 protects the intestinal mucosa from pathogen attack through various pathways and inflammatory protective factors, thereby preventing the occurrence of CRC.

7. NLRC4 GOF mutation

Mutations in NLRC4 resulting in GOF have been associated with several conditions, including early-onset recurrent fever, recurrent macrophage activation syndrome, enterocolitis and even cancer (15,16,18,60,120,127). The NLRC4 (Ala160Thr) variant can cause recessive immune dysregulation and autoinflammation, or act as a heterozygous risk factor for the development of ulcerative colitis. This variant often affects epithelial cells and colon tissue (15).

The NLRC4 protein features a CARD at its N-terminus, a central NBD and a LRR domain (128). Mutations frequently occur in the NBD and LRR domains. Bardet et al (128) identified two mutations in the NBD: p.Arg207Lys and p.Thr337Asn (Fig. 4). Romberg et al (59) reported a p.Val341Ala mutation in the NBD, while Barsalou et al (62) identified a p.Val341Leu mutation. Additionally, the p.Ser445Pro mutation at the NBD was described by Volker-Touw et al (129). Other mutations in the NBD include p.Val341Ala, p.Thr337Ser, p.His443Pro and p.Ser445Pro, as noted in the literature (1,2,58,60,129). In the LRR domain, mutations such as p.Gln657Leu (61) and p.Trp655Cys (130) have been observed. Some mutations induce clinical symptoms, while others do not (16,128,131). Mice expressing a murine NLRC4 (Val341Ala) mutant showed elevated systemic IL-18 levels, indicating that the mechanisms by which this mutant induces elevated IL-18 production are conserved between humans and mice. However, while experiments that are germfree or with infections argue against a role for commensal or pathogenic bacteria, identifying the triggers and mechanisms that synergize with IL-18 to drive NLRC4 (Val341Ala)-associated pathologies requires further research using this NLRC4 (Val341Ala) mouse model (132). The NLRC4 Val341Ala mutation is closely related to colitis, increasing IL-18 levels and potentially raising the risk of CRC from a mechanistic perspective (132). Research on the elevated expression level of Val431Ala in the tissues of patients with CRC is lacking, as is a direct link between this factor and CRC. To date, few studies have reported an association between NLRC4 GOF mutations and CRC, with only 1 study indicating that NLRC4 mutations were present in 4% of CRC cases (24). Therefore, the strategies for treating CRC that rely on NLRC4 are currently in the basic research stage, and there are not yet many clinically relevant studies. This is also one of the purposes of writing the present review.

8. Conclusions, limitations and perspective

NLRC4 is a significant inflammasome that protects against CRC through various signaling pathways and mechanisms. Mutations in NLRC4 may contribute to CRC development and could be associated with a poor prognosis. There is a lack of original studies on NLRC4 mutations and their prognosis in CRC due to some limited conditions in our institution (such as no funding support and lack of suitable patients and samples). However, the present review highlights the need to explore the relationship between NLRC4 mutations and CRC further. The clinical utility of detecting NLRC4 in the serum and tissue of patients with CRC requires additional investigation by researchers and clinicians. NLRC4 contributes to the suppression of CRC, which is the conclusion from numerous experiments and partial clinical study. However, the development of a NLRC4-dependent novel strategy to treat patients with CRC also requires further study. For instance, investigations into how to prevent NLRC4 mutations, how to block their induction of CRC and how to improve the treatment of CRC with serum or tissue NLRC4 mutations are needed.

Acknowledgments

The authors thank Mrs. Liqing Li (Central Laboratory, Huzhou Central Hospital, Huzhou, Zhejiang 313003, P.R. China) for her valuable suggestions on the manuscript.

Availability of data and materials

Not applicable.

Authors' contributions

GT, YS, HL, HQ and ZT participated in collecting the literature; GT wrote the paper and drew the figures; YS summarized the tables. HL, HQ and ZT participated in revising the review. All authors read and approved the final version of the manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Figure 1 Literature search process. CRC, colorectal cancer; IBD, inflammatory bowel disease; NLRC4, Nod-like receptor C4.

Figure 2 Schematic depiction of the architecture of NLRC4, showing the initial and terminal residues for each distinct domain of the protein (19). CARD, caspase-activating and recruitment domain; LRR, leucine-rich repeat; NLRC4, Nod-like receptor C4; NOD, nucleotide-binding oligomerization domain.

Figure 3 Inflammasome sensors have diverse roles in tumorigenesis. The NLRP1b, NLRP3 and NLRP6 inflammasomes facilitate the production of IL-18, which helps protect against colorectal cancer associated with colitis. IL-18 also triggers the anticancer activity of natural killer cells against metastatic colonic tumor cells, reduces the levels of IL-22BP and may prevent the establishment of colitis-inducing microbiota, potentially through its impact on MUC2 secretion by goblet cells. The NLRP3 inflammasome, along with the IL-1β/IL-1 receptor signaling pathway, drives a T-cell response against transplantable tumor cells. In mice, NAIP1-6 proteins regulate STAT3 phosphorylation and the transcription of genes involved in anti-apoptotic and cell proliferation mechanisms. NLRC4 inhibits melanoma growth by enhancing macrophage inflammation and increasing IFNγ production in T cells. AIM2 suppresses AKT and cMyc phosphorylation, limiting stem cell proliferation and preventing colonization by colitis-promoting microbiota (83). AIM2, absent in melanoma 2; IL-22BP, IL-22 binding protein; MUC2, mucin 2; NLRC4, Nod-like receptor C4; NOD, nucleotide-binding oligomerization domain; NLRP, NLR family pyrin domain containing.

Figure 4 Diagram of NLRC4 GOF mutations (120). CARD, caspase-activating and recruitment domain; GOF, gain-of-function; LRR, leucine-rich repeat; NBD, nucleotide-binding domain; NLRC4, Nod-like receptor C4.

Table I NLRC4 function in inflammation and CRC.

NLRC4 functionsa	Summaries of the relative factors and signaling pathways	(Refs.)	
An innate cytosolic sensor (NLRC4 activated)	Caspase-1 (+), pyroptosis (+)	(5)	
NAIPs (+)	(15)	
T3SS (+)	(28,46-48)	
IRF8 (+)	(37)	
Protect host defense (NLRC4 deficient mice) (NLRC4 protects host against pathogens)	S. Typhimurium↑	(49)	
C. Rodentium↑	(50)	
Salmonella (+)	(22,25)	
Citrobacter (+)	(11,51)	
Legionella (+)	(28,52)	
Auto-inflammatory disease (NLRC4 over activation) (NLRC4 mutant)	IL-1β↑, IL-18↑	(53)	
HD1 (+)	(40,54)	
Neutrophils↑	(55,56)	
NLRC4 in pyroptosis, apoptosis, necroptosis, and PANoptosis	IL-1β maturation, caspase-1 (+)	(70)	
PARP1 (+)	(72)	
GSDMD (+), MLKL (+), Caspase-1,3,7,8 (+)	(59)	
NLRC4 and CRC	CAC (increasing or not)	(74-76)	
DSS-induced colitis (more sensitive)	(78)	
No role in the progression of melanoma	(80,81)	
Suppressor in CRC	(18,77)	
High expression associated with good prognosis of CRC	(18)	
a The text in brackets indicates the experimental conditions. NLRC4, Nod like receptor C4; CRC, colorectal cancer; NAIPs, the NLR family apoptosis inhibitory proteins; T3SS, type III secretion system; IRF8, interferon regulatory factor 8; HD1, the helical domain 1; PARP1, poly (ADP-ribose) polymerase 1; GSDMD, gasdermin D; MLKL, mixed lineage kinase domain-like pseudokinase; CAC, colitis-associated cancer; DSS, dextran sulfate sodium.

Table II Possible signaling pathway and mechanisms of NLRC4 in CRC.

Signaling pathway	Mechanisms	(Refs.)	
Caspase-1 signaling pathway	NLRC4 in pyroptosis, apoptosis, necroptosis and PANoptosis; an innate cytosolic sensor; protects intestinal epithelial cells.	(67,74-76,83-86)	
NLRP3/IL-8 signaling pathway	IL-1β (+) and IL-18 (+); caspase-1 (+); AIM2 and pyrin; ASC (+); GSDMD (+); IRF8↑, NAIPs helps recognize PAMPs; IFI16, DDX58 promote caspase-1; IL-1β↑, IL-18↑; NLRC4 and MCP2/CCL8 in serum↑; epithelium-autonomous NAIP/NLRC4↑.	(13,70,83,88-95)	
IL1β/IL1 receptor signaling axis	Activates CD8+ T-cell; CD8+ T-cell↑; suppress CRC cells; killing CRC cell is unknown.	(96)	
NAIP1-6 signaling pathway	Inhibiting cell proliferation and promoting apoptosis; enhancing inflammatory signaling in macrophages; increases the generation of IFNγ in CD8+ and CD4+ T cells.	(74,77,79,83,97)	
p53 signaling pathway	Acting as a tumor suppressor; involved in apoptosis, DNA repair and cell cycle management; inhibiting the development of tumor cells.	(97-109)	
AIM2, absent in melanoma 2; ASC, apoptosis-associated speck-like protein; GSDMD, gasdermin D; IRF8, interferon regulatory factor 8; NAIPs, the NLR family apoptosis inhibitory proteins; PAMPs, pathogen-associated molecular patterns; IFI16, IFNγ-inducible protein 16; DDX58, retinoic acid-inducible gene I protein; MCP2/CCL8, monocyte chemoattractant protein 2/chemokine (C-C motif) ligand 8.
==== Refs
References

1 Poyet JL Srinivasula SM Tnani M Razmara M Fernandes-Alnemri T Alnemri ES Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1 J Biol Chem 276 28309 28313 2001 10.1074/jbc.C100250200 11390368
2 Duncan JA Canna SW The NLRC4 inflammasome Immunol Rev 281 115 123 2018 10.1111/imr.12607 29247997
3 Gutierrez O Pipaon C Fernandez-Luna JL Ipaf is upregulated by tumor necrosis factor-alpha in human leukemia cells FEBS Lett 568 79 82 2004 10.1016/j.febslet.2004.04.095 15196924
4 Sadasivam S Gupta S Radha V Batta K Kundu TK Swarup G Caspase-1 activator Ipaf is a p53-inducible gene involved in apoptosis Oncogene 24 627 636 2005 10.1038/sj.onc.1208201 15580302
5 Mariathasan S Newton K Monack DM Vucic D French DM Lee WP Roose-Girma M Erickson S Dixit VM Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf Nature 430 213 218 2004 10.1038/nature02664 15190255
6 Hu Z Yan C Liu P Huang Z Ma R Zhang C Wang R Zhang Y Martinon F Miao D Crystal structure of NLRC4 reveals its autoinhibition mechanism Science 341 172 175 2013 10.1126/science.1236381 23765277
7 Wang X Shaw DK Hammond HL Sutterwala FS Rayamajhi M Shirey KA Perkins DJ Bonventre JV Velayutham TS Evans SM The prostaglandin E2-EP3 receptor axis regulates anaplasma phagocytophilum-mediated NLRC4 inflammasome activation PLoS Pathog 12 e1005803 2016 10.1371/journal.ppat.1005803 27482714
8 Zhang L Chen S Ruan J Wu J Tong AB Yin Q Li Y David L Lu A Wang WL Cryo-EM structure of the activated NAIP2-NLRC4 inflammasome reveals nucleated polymerization Science 350 404 409 2015 10.1126/science.aac5789 26449474
9 Sellin ME Müller AA Felmy B Dolowschiak T Diard M Tardivel A Maslowski KM Hardt WD Epithelium-intrinsic NAIP/NLRC4 inflammasome drives infected enterocyte expulsion to restrict Salmonella replication in the intestinal mucosa Cell Host Microbe 16 237 248 2014 10.1016/j.chom.2014.07.001 25121751
10 Rauch I Deets KA Ji DX von Moltke J Tenthorey JL Lee AY Philip NH Ayres JS Brodsky IE Gronert K Vance RE NAIP-NLRC4 inflammasomes coordinate intestinal epithelial cell expulsion with eicosanoid and IL-18 release via activation of caspase-1 and -8 Immunity 46 649 659 2017 10.1016/j.immuni.2017.03.016 28410991
11 Nordlander S Pott J Maloy KJ NLRC4 expression in intestinal epithelial cells mediates protection against an enteric pathogen Mucosal Immunol 7 775 785 2014 10.1038/mi.2013.95 24280936
12 Janowski AM Kolb R Zhang W Sutterwala FS Beneficial and detrimental roles of NLRs in carcinogenesis Front Immunol 4 370 2013 10.3389/fimmu.2013.00370 24273542
13 Dupaul-Chicoine J Yeretssian G Doiron K Bergstrom KSB McIntire CR LeBlanc PM Meunier C Turbide C Gros P Beauchemin N Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases Immunity 32 367 378 2010 10.1016/j.immuni.2010.02.012 20226691
14 Zhiyu W Wang N Wang Q Peng C Zhang J Liu P Ou A Zhong S Cordero MD Lin Y The inflammasome: An emerging therapeutic oncotarget for cancer prevention Oncotarget 7 50766 50780 2016 10.18632/oncotarget.9391 27206676
15 Steiner A Reygaerts T Pontillo A Ceccherini I Moecking J Moghaddas F Davidson S Caroli F Grossi A Castro FFM Recessive NLRC4-autoinflammatory disease reveals an ulcerative colitis locus J Clin Immunol 42 325 335 2022 10.1007/s10875-021-01175-4 34783940
16 Wang J Ye Q Zheng W Yu X Luo F Fang R Shangguan Y Du Z Lee PY Jin T Zhou Q Low-ratio somatic NLRC4 mutation causes late-onset autoinflammatory disease Ann Rheum Dis 81 1173 1178 2022 10.1136/annrheumdis-2021-221708 35428651
17 Wu C Zhao J Wang X Wang Y Zhang W Zhu G A novel pyroptosis related genes signature for predicting prognosis and estimating tumor immune microenvironment in lung adenocarcinoma Transl Cancer Res 11 2647 2659 2022 10.21037/tcr-22-327 36093538
18 Sundaram B Kanneganti TD Advances in understanding activation and function of the NLRC4 inflammasome Int J Mol Sci 22 1048 2021 10.3390/ijms22031048 33494299
19 Jin H Kim HJ NLRC4, ASC and caspase-1 are inflammasome components that are mediated by P2Y2R activation in breast cancer cells Int J Mol Sci 21 3337 2020 10.3390/ijms21093337 32397236
20 Lim J Kim MJ Park Y Ahn JW Hwang SJ Moon JS Cho KG Kwack K Upregulation of the NLRC4 inflammasome contributes to poor prognosis in glioma patients Sci Rep 9 7895 2019 10.1038/s41598-019-44261-9 31133717
21 Sonohara F Inokawa Y Kanda M Nishikawa Y Yamada S Fujii T Sugimoto H Kodera Y Nomoto S Association of inflammasome components in background liver with poor prognosis after curatively-resected hepatocellular carcinoma Anticancer Res 37 293 300 2017 10.21873/anticanres.11320 28011505
22 Janowski AM Colegio OR Hornick EE McNiff JM Martin MD Badovinac VP Norian LA Zhang W Cassel SL Sutterwala FS NLRC4 suppresses melanoma tumor progression independently of inflammasome activation J Clin Invest 126 3917 3928 2016 10.1172/JCI86953 27617861
23 Hu B Elinav E Huber S Booth CJ Strowig T Jin C Eisenbarth SC Flavell RA Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4 Proc Natl Acad Sci USA 107 21635 21640 2010 10.1073/pnas.1016814108 21118981
24 Peng L Zhu N Wang D Zhou Y Liu Y Comprehensive analysis of prognostic value and immune infiltration of NLRC4 and CASP1 in colorectal cancer Int J Gen Med 15 5425 5440 2022 10.2147/IJGM.S353380 35692355
25 Abdelaziz DH Amr K Amer AO Nlrc4/Ipaf/CLAN/CARD12: More than a flagellin sensor Int J Biochem Cell Biol 42 789 791 2010 10.1016/j.biocel.2010.01.003 20067841
26 Sun Q Scott MJ Caspase-1 as a multifunctional inflammatory mediator: Noncytokine maturation roles J Leukoc Biol 100 961 967 2016 10.1189/jlb.3MR0516-224R 27450556
27 Lamkanfi M Kanneganti TD Franchi L Núñez G Caspase-1 inflammasomes in infection and inflammation J Leukoc Biol 82 220 225 2007 10.1189/jlb.1206756 17442855
28 Naseer N Zhang J Bauer R Constant DA Nice TJ Brodsky IE Rauch I Shin S Salmonella enterica Serovar typhimurium induces NAIP/NLRC4- and NLRP3/ASC-independent, caspase-4-dependent inflammasome activation in human intestinal epithelial cells Infect Immun 90 e0066321 2022 10.1128/iai.00663-21 35678562
29 Naseer N Egan MS Reyes Ruiz VM Scott WP Hunter EN Demissie T Rauch I Brodsky IE Shin S Human NAIP/NLRC4 and NLRP3 inflammasomes detect Salmonella type III secretion system activities to restrict intracellular bacterial replication PLoS Pathog 18 e1009718 2022 10.1371/journal.ppat.1009718 35073381
30 Gram AM Wright JA Pickering RJ Lam NL Booty LM Webster SJ Bryant CE Salmonella flagellin activates NAIP/NLRC4 and canonical NLRP3 inflammasomes in human macrophages J Immunol 206 631 640 2021 10.4049/jimmunol.2000382 33380493
31 Schell U Simon S Hilbi H Inflammasome recognition and regulation of the Legionella flagellum Curr Top Microbiol Immunol 397 161 181 2016 27460809
32 Cerqueira DM Pereira MS Silva AL Cunha LD Zamboni DS Caspase-1 but not caspase-11 is required for NLRC4-mediated pyroptosis and restriction of infection by flagellated Legionella species in mouse macrophages and in vivo J Immunol 195 2303 2311 2015 10.4049/jimmunol.1501223 26232428
33 Zhao Y Yang J Shi J Gong YN Lu Q Xu H Liu L Shao F The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus Nature 477 596 600 2011 10.1038/nature10510 21918512
34 Pereira MSF Morgantetti GF Massis LM Horta CV Hori JI Zamboni DS Activation of NLRC4 by flagellated bacteria triggers caspase-1-dependent and -independent responses to restrict Legionella pneumophila replication in macrophages and in vivo J Immunol 187 6447 6455 2011 10.4049/jimmunol.1003784 22079982
35 Luchetti G Roncaioli JL Chavez RA Schubert AF Kofoed EM Reja R Cheung TK Liang Y Webster JD Lehoux I Shigella ubiquitin ligase IpaH7.8 targets gasdermin D for degradation to prevent pyroptosis and enable infection Cell Host Microbe 29 1521 1530.e10 2021 10.1016/j.chom.2021.08.010 34492225
36 Mitchell PS Roncaioli JL Turcotte EA Goers L Chavez RA Lee AY Lesser CF Rauch I Vance RE NAIP-NLRC4-deficient mice are susceptible to shigellosis Elife 9 e59022 2020 10.7554/eLife.59022 33074100
37 Hermansson AK Paciello I Bernardini ML The orchestra and its maestro: Shigella's fine-tuning of the inflammasome platforms Curr Top Microbiol Immunol 397 91 115 2016 27460806
38 Suzuki S Mimuro H Kim M Ogawa M Ashida H Toyotome T Franchi L Suzuki M Sanada T Suzuki T Shigella IpaH7.8 E3 ubiquitin ligase targets glomulin and activates inflammasomes to demolish macrophages Proc Natl Acad Sci USA 111 E4254 E4263 2014 10.1073/pnas.1324021111 25246571
39 Santoni K Pericat D Gorse L Buyck J Pinilla M Prouvensier L Bagayoko S Hessel A Leon-Icaza SA Bellard E Caspase-1-driven neutrophil pyroptosis and its role in host susceptibility to Pseudomonas aeruginosa PLoS Pathog 18 e1010305 2022 10.1371/journal.ppat.1010305 35849616
40 Mohamed MF Gupta K Goldufsky JW Roy R Callaghan LT Wetzel DM Kuzel TM Reiser J Shafikhani SH CrkII/Abl phosphorylation cascade is critical for NLRC4 inflammasome activity and is blocked by Pseudomonas aeruginosa ExoT Nat Commun 13 1295 2022 10.1038/s41467-022-28967-5 35277504
41 Graustein AD Berrington WR Buckingham KJ Nguyen FK Joudeh LL Rosenfeld M Bamshad MJ Gibson RL Hawn TR Emond MJ Inflammasome genetic variants, macrophage function, and clinical outcomes in cystic fibrosis Am J Respir Cell Mol Biol 65 157 166 2021 10.1165/rcmb.2020-0257OC 33848452
42 Karki R Lee E Place D Samir P Mavuluri J Sharma BR Balakrishnan A Malireddi RKS Geiger R Zhu Q IRF8 regulates transcription of Naips for NLRC4 inflammasome activation Cell 173 920 933.e13 2018 10.1016/j.cell.2018.02.055 29576451
43 Mascarenhas DPA Cerqueira DM Pereira MSF Castanheira FVS Fernandes TD Manin GZ Cunha LD Zamboni DS Inhibition of caspase-1 or gasdermin-D enable caspase-8 activation in the Naip5/NLRC4/ASC inflammasome PLoS Pathog 13 e1006502 2017 10.1371/journal.ppat.1006502 28771586
44 Furuoka M Ozaki K Sadatomi D Mamiya S Yonezawa T Tanimura S Takeda K TNF-α induces caspase-1 activation independently of simultaneously induced NLRP3 in 3T3-L1 cells J Cell Physiol 231 2761 2767 2016 10.1002/jcp.25385 26989816
45 Hua L Liang S Zhou Y Wu X Cai H Liu Z Ou Y Chen Y Chen X Yan Y Artemisinin-derived artemisitene blocks ROS-mediated NLRP3 inflammasome and alleviates ulcerative colitis Int Immunopharmacol 113 109431 2022 10.1016/j.intimp.2022.109431 36384076
46 Taman H Fenton CG Anderssen E Florholmen J Paulssen RH DNA hypo-methylation facilitates anti-inflammatory responses in severe ulcerative colitis PLoS One 16 e0248905 2021 10.1371/journal.pone.0248905 33793617
47 Miao EA Mao DP Yudkovsky N Bonneau R Lorang CG Warren SE Leaf IA Aderem A Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome Proc Natl Acad Sci USA 107 3076 3080 2010 10.1073/pnas.0913087107 20133635
48 Miao EA Alpuche-Aranda CM Dors M Clark AE Bader MW Miller SI Aderem A Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf Nat Immunol 7 569 575 2006 10.1038/ni1344 16648853
49 Endrizzi MG Hadinoto V Growney JD Miller W Dietrich WF Genomic sequence analysis of the mouse Naip gene array Genome Res 10 1095 1102 2000 10.1101/gr.10.8.1095 10958627
50 Kofoed EM Vance RE Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity Nature 477 592 595 2011 10.1038/nature10394 21874021
51 Rayamajhi M Zak DE Chavarria-Smith J Vance RE Miao EA Cutting edge: Mouse NAIP1 detects the type III secretion system needle protein J Immunol 191 3986 3989 2013 10.4049/jimmunol.1301549 24043898
52 Yang J Zhao Y Shi J Shao F Human NAIP and mouse NAIP1 recognize bacterial type III secretion needle protein for inflammasome activation Proc Natl Acad Sci USA 110 14408 14413 2013 10.1073/pnas.1306376110 23940371
53 Kortmann J Brubaker SW Monack DM Cutting edge: Inflammasome activation in primary human macrophages is dependent on flagellin J Immunol 195 815 819 2015 10.4049/jimmunol.1403100 26109648
54 Broz P Newton K Lamkanfi M Mariathasan S Dixit VM Monack DM Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella J Exp Med 207 1745 1755 2010 10.1084/jem.20100257 20603313
55 Liu Z Zaki MH Vogel P Gurung P Finlay BB Deng W Lamkanfi M Kanneganti TD Role of inflammasomes in host defense against Citrobacter rodentium infection J Biol Chem 287 16955 16964 2012 10.1074/jbc.M112.358705 22461621
56 Man SM Karki R Briard B Burton A Gingras S Pelletier S Kanneganti TD Differential roles of caspase-1 and caspase-11 in infection and inflammation Sci Rep 7 45126 2017 10.1038/srep45126 28345580
57 Gonçalves AV Margolis SR Quirino GFS Mascarenhas DPA Rauch I Nichols RD Ansaldo E Fontana MF Vance RE Zamboni DS Gasdermin-D and caspase-7 are the key caspase-1/8 substrates downstream of the NAIP5/NLRC4 inflammasome required for restriction of Legionella pneumophila PLoS Pathog 15 e1007886 2019 10.1371/journal.ppat.1007886 31251782
58 Canna SW de Jesus AA Gouni S Brooks SR Marrero B Liu Y DiMattia MA Zaal KJ Sanchez GA Kim H An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome Nat Genet 46 1140 1146 2014 10.1038/ng.3089 25217959
59 Romberg N Al Moussawi K Nelson-Williams C Stiegler AL Loring E Choi M Overton J Meffre E Khokha MK Huttner AJ Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation Nat Genet 46 1135 1139 2014 10.1038/ng.3066 25217960
60 Kitamura A Sasaki Y Abe T Kano H Yasutomo K An inherited mutation in NLRC4 causes autoinflammation in human and mice J Exp Med 211 2385 2396 2014 10.1084/jem.20141091 25385754
61 Chear CT Nallusamy R Canna SW Chan KC Baharin MF Hishamshah M Ghani H Ripen AM Mohamad SB A novel de novo NLRC4 mutation reinforces the likely pathogenicity of specific LRR domain mutation Clin Immunol 211 108328 2020 10.1016/j.clim.2019.108328 31870725
62 Barsalou J Blincoe A Fernandez I Dal-Soglio D Marchitto L Selleri S Haddad E Benyoucef A Touzot F Rapamycin as an adjunctive therapy for NLRC4 associated macrophage activation syndrome Front Immunol 9 2162 2018 10.3389/fimmu.2018.02162 30319625
63 Wang Y Gao W Shi X Ding J Liu W He H Wang K Shao F Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin Nature 547 99 103 2017 10.1038/nature22393 28459430
64 Christgen S Zheng M Kesavardhana S Karki R Malireddi RKS Banoth B Place DE Briard B Sharma BR Tuladhar S Identification of the PANoptosome: A molecular platform triggering pyroptosis, apoptosis, and necroptosis (PANoptosis) Front Cell Infect Microbiol 10 237 2020 10.3389/fcimb.2020.00237 32547960
65 Pandian N Kanneganti TD PANoptosis: A unique innate immune inflammatory cell death modality J Immunol 209 1625 1633 2022 10.4049/jimmunol.2200508 36253067
66 Pan H Pan J Li P Gao J Characterization of PANoptosis patterns predicts survival and immunotherapy response in gastric cancer Clin Immunol 238 109019 2022 10.1016/j.clim.2022.109019 35470064
67 Lin JF Hu PS Wang YY Tan YT Yu K Liao K Wu QN Li T Meng Q Lin JZ Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis Signal Transduct Target Ther 7 54 2022 10.1038/s41392-022-00889-0 35221331
68 Wang Y Kanneganti TD From pyroptosis, apoptosis and necroptosis to PANoptosis: A mechanistic compendium of programmed cell death pathways Comput Struct Biotechnol J 19 4641 4657 2021 10.1016/j.csbj.2021.07.038 34504660
69 Place DE Lee S Kanneganti TD PANoptosis in microbial infection Curr Opin Microbiol 59 42 49 2021 10.1016/j.mib.2020.07.012 32829024
70 Lee S Karki R Wang Y Nguyen LN Kalathur RC Kanneganti TD AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence Nature 597 415 419 2021 10.1038/s41586-021-03875-8 34471287
71 Karki R Sundaram B Sharma BR Lee S Malireddi RKS Nguyen LN Christgen S Zheng M Wang Y Samir P ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis Cell Rep 37 109858 2021 10.1016/j.celrep.2021.109858 34686350
72 Jiang W Deng Z Dai X Zhao W PANoptosis: A new insight into oral infectious diseases Front Immunol 12 789610 2021 10.3389/fimmu.2021.789610 34970269
73 Zheng M Kanneganti TD The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis) Immunol Rev 297 26 38 2020 10.1111/imr.12909 32729116
74 Samir P Malireddi RKS Kanneganti TD The PANoptosome: A deadly protein complex driving pyroptosis, apoptosis, and necroptosis (PANoptosis) Front Cell Infect Microbiol 10 238 2020 10.3389/fcimb.2020.00238 32582562
75 Chen H Deng Y Gan X Li Y Huang W Lu L Wei L Su L Luo J Zou B NLRP12 collaborates with NLRP3 and NLRC4 to promote pyroptosis inducing ganglion cell death of acute glaucoma Mol Neurodegener 15 26 2020 10.1186/s13024-020-00372-w 32295623
76 Pistritto G Trisciuoglio D Ceci C Garufi A D'Orazi G Apoptosis as anticancer mechanism: Function and dysfunction of its modulators and targeted therapeutic strategies Aging (Albany NY) 8 603 619 2016 10.18632/aging.100934 27019364
77 Yan J Wan P Choksi S Liu ZG Necroptosis and tumor progression Trends Cancer 8 21 27 2022 10.1016/j.trecan.2021.09.003 34627742
78 Karki R Kanneganti TD Diverging inflammasome signals in tumorigenesis and potential targeting Nat Rev Cancer 19 197 214 2019 10.1038/s41568-019-0123-y 30842595
79 Allen IC TeKippe EM Woodford RM Uronis JM Holl EK Rogers AB Herfarth HH Jobin C Ting JP The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer J Exp Med 207 1045 1056 2010 10.1084/jem.20100050 20385749
80 Zaki MH Boyd KL Vogel P Kastan MB Lamkanfi M Kanneganti TD The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis Immunity 32 379 391 2010 10.1016/j.immuni.2010.03.003 20303296
81 Zaki MH Vogel P Body-Malapel M Lamkanfi M Kanneganti TD IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation J Immunol 185 4912 4920 2010 10.4049/jimmunol.1002046 20855874
82 Carvalho FA Nalbantoglu I Aitken JD Uchiyama R Su Y Doho GH Vijay-Kumar M Gewirtz AT Cytosolic flagellin receptor NLRC4 protects mice against mucosal and systemic challenges Mucosal Immunol 5 288 298 2012 10.1038/mi.2012.8 22318495
83 Karki R Man SM Kanneganti TD Inflammasomes and cancer Cancer Immunol Res 5 94 99 2017 10.1158/2326-6066.CIR-16-0269 28093447
84 Tenthorey JL Chavez RA Thompson TW Deets KA Vance RE Rauch I NLRC4 inflammasome activation is NLRP3- and phosphorylation-independent during infection and does not protect from melanoma J Exp Med 217 e20191736 2020 10.1084/jem.20191736 32342103
85 Ohashi K Wang Z Yang YM Billet S Tu W Pimienta M Cassel SL Pandol SJ Lu SC Sutterwala FS NOD-like receptor C4 inflammasome regulates the growth of colon cancer liver metastasis in NAFLD Hepatology 70 1582 1599 2019 10.1002/hep.30693 31044438
86 Chen GY Núñez G Inflammasomes in intestinal inflammation and cancer Gastroenterology 141 1986 1999 2011 10.1053/j.gastro.2011.10.002 22005480
87 Peng L Youwei R Yanghong Z Research progress of NLRC4 and colorectal cancer J Hubei Univ Sci Technol (Med Sci) 36 176 179 2022 10.16751/j.cnki.2095-4646.2022.02.176
88 Bast A Krause K Schmidt IHE Pudla M Brakopp S Hopf V Breitbach K Steinmetz I Caspase-1-dependent and -independent cell death pathways in Burkholderia pseudomallei infection of macrophages PLoS Pathog 10 e1003986 2014 10.1371/journal.ppat.1003986 24626296
89 Freeman L Guo H David CN Brickey WJ Jha S Ting JPY NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes J Exp Med 214 1351 1370 2017 10.1084/jem.20150237 28404595
90 Guo Q Wu Y Hou Y Liu Y Liu T Zhang H Fan C Guan H Li Y Shan Z Teng W Cytokine secretion and pyroptosis of thyroid follicular cells mediated by enhanced NLRP3, NLRP1, NLRC4, and AIM2 inflammasomes are associated with autoimmune thyroiditis Front Immunol 9 1197 2018 10.3389/fimmu.2018.01197 29915579
91 Chiarini A Armato U Gui L Dal Prà I 'Other than NLRP3' inflammasomes: Multiple roles in brain disease Neuroscientist 30 23 48 2024 10.1177/10738584221106114 35815856
92 Salcedo R Worschech A Cardone M Jones Y Gyulai Z Dai RM Wang E Ma W Haines D O'HUigin C MyD88-mediated signaling prevents development of adenocarcinomas of the colon: Role of interleukin 18 J Exp Med 207 1625 1636 2010 10.1084/jem.20100199 20624890
93 Takagi H Kanai T Okazawa A Kishi Y Sato T Takaishi H Inoue N Ogata H Iwao Y Hoshino K Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice Scand J Gastroenterol 38 837 844 2003 10.1080/00365520310004047 12940437
94 Chen GY Liu M Wang F Bertin J Núñez G A functional role for Nlrp6 in intestinal inflammation and tumorigenesis J Immunol 186 7187 7194 2011 10.4049/jimmunol.1100412 21543645
95 Wilson JE Petrucelli AS Chen L Koblansky AA Truax AD Oyama Y Rogers AB Brickey WJ Wang Y Schneider M Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt Nat Med 21 906 913 2015 10.1038/nm.3908 26107252
96 Bakhshi S Shamsi S MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes Int Immunopharmacol 106 108595 2022 10.1016/j.intimp.2022.108595 35124417
97 Cai Y Chen J Liu J Zhu K Xu Z Shen J Wang D Chu L Identification of six hub genes and two key pathways in two rat renal fibrosis models based on bioinformatics and RNA-seq transcriptome analyses Front Mol Biosci 9 1035772 2022 10.3389/fmolb.2022.1035772 36438657
98 Di Q Zhao X Tang H Li X Xiao Y Wu H Wu Z Quan J Chen W USP22 suppresses the NLRP3 inflammasome by degrading NLRP3 via ATG5-dependent autophagy Autophagy 19 873 885 2023 10.1080/15548627.2022.2107314 35900990
99 Kolb R Phan L Borcherding N Liu Y Yuan F Janowski AM Xie Q Markan KR Li W Potthoff MJ Obesity-associated NLRC4 inflammasome activation drives breast cancer progression Nat Commun 7 13007 2016 10.1038/ncomms13007 27708283
100 Ghiringhelli F Apetoh L Tesniere A Aymeric L Ma Y Ortiz C Vermaelen K Panaretakis T Mignot G Ullrich E Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors Nat Med 15 1170 1178 2009 10.1038/nm.2028 19767732
101 Allam R Maillard MH Tardivel A Chennupati V Bega H Yu CW Velin D Schneider P Maslowski KM Epithelial NAIPs protect against colonic tumorigenesis J Exp Med 212 369 383 2015 10.1084/jem.20140474 25732303
102 Güllülü Ö Hehlgans S Rödel C Fokas E Rödel F Tumor suppressor protein p53 and inhibitor of apoptosis proteins in colorectal cancer-A promising signaling network for therapeutic interventions Cancers (Basel) 13 624 2021 10.3390/cancers13040624 33557398
103 Lee C Do HTT Her J Kim Y Seo D Rhee I Inflammasome as a promising therapeutic target for cancer Life Sci 231 116593 2019 10.1016/j.lfs.2019.116593 31228512
104 Naqishbandi AM Cytotoxic and apoptotic potential of gemini-chrysophanol nanoparticles against human colorectal cancer HCT-116 cell lines BMC Pharmacol Toxicol 23 56 2022 10.1186/s40360-022-00597-z 35870982
105 Moazzendizaji S Sevbitov A Ezzatifar F Jalili HR Aalii M Hemmatzadeh M Aslani S Gholizadeh Navashenaq J Safari R Hosseinzadeh R microRNAs: Small molecules with a large impact on colorectal cancer Biotechnol Appl Biochem 69 1893 1908 2022 10.1002/bab.2255 34550619
106 Elrebehy MA Al-Saeed S Gamal S El-Sayed A Ahmed AA Waheed O Ismail A El-Mahdy HAM Sallam AM Doghish AS miRNAs as cornerstones in colorectal cancer pathogenesis and resistance to therapy: A spotlight on signaling pathways interplay-a review Int J Biol Macromol 214 583 600 2022 10.1016/j.ijbiomac.2022.06.134 35768045
107 Dai F Guo M Shao Y Li C Vibrio splendidus flagellin C binds tropomodulin to induce p38 MAPK-mediated p53-dependent coelomocyte apoptosis in Echinodermata J Biol Chem 298 102091 2022 10.1016/j.jbc.2022.102091 35654141
108 Mello SS Attardi LD Deciphering p53 signaling in tumor suppression Curr Opin Cell Biol 51 65 72 2018 10.1016/j.ceb.2017.11.005 29195118
109 Raghu D Karunagaran D Plumbagin downregulates Wnt signaling independent of p53 in human colorectal cancer cells J Nat Prod 77 1130 1134 2014 10.1021/np4010085 24828199
110 Golubovskaya VM Cance WG Targeting the p53 pathway Surg Oncol Clin N Am 22 747 764 2013 10.1016/j.soc.2013.06.003 24012397
111 Stegh AH Targeting the p53 signaling pathway in cancer therapy-the promises, challenges and perils Expert Opin Ther Targets 16 67 83 2012 10.1517/14728222.2011.643299 22239435
112 Morandell S Yaffe MB Exploiting synthetic lethal interactions between DNA damage signaling, checkpoint control, and p53 for targeted cancer therapy Prog Mol Biol Transl Sci 110 289 314 2012 10.1016/B978-0-12-387665-2.00011-0 22749150
113 Golubovskaya VM Cance WG Focal adhesion kinase and p53 signaling in cancer cells Int Rev Cytol 263 103 153 2007 10.1016/S0074-7696(07)63003-4 17725966
114 El-Deiry WS Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling Cell Death Differ 8 1066 1075 2001 10.1038/sj.cdd.4400943 11687885
115 Bates S Vousden KH p53 in signaling checkpoint arrest or apoptosis Curr Opin Genet Dev 6 12 18 1996 10.1016/S0959-437X(96)90004-0 8791489
116 Khan M Ai M Du K Song J Wang B Lin J Ren A Chen C Huang Z Qiu W Pyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective Front Immunol 13 1062225 2022 10.3389/fimmu.2022.1062225 36605187
117 Ding J Wang K Liu W She Y Sun Q Shi J Sun H Wang DC Shao F Pore-forming activity and structural autoinhibition of the gasdermin family Nature 535 111 116 2016 10.1038/nature18590 27281216
118 Liu X Zhang Z Ruan J Pan Y Magupalli VG Wu H Lieberman J Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores Nature 535 153 158 2016 10.1038/nature18629 27383986
119 Broz P Dixit VM Inflammasomes: Mechanism of assembly, regulation and signalling Nat Rev Immunol 16 407 420 2016 10.1038/nri.2016.58 27291964
120 Kay C Wang R Kirkby M Man SM Molecular mechanisms activating the NAIP-NLRC4 inflammasome: Implications in infectious disease, autoinflammation, and cancer Immunol Rev 297 67 82 2020 10.1111/imr.12906 32729154
121 Man SM Inflammasomes in the gastrointestinal tract: Infection, cancer and gut microbiota homeostasis Nat Rev Gastroenterol Hepatol 15 721 737 2018 10.1038/s41575-018-0054-1 30185915
122 Irak K Bayram M Cifci S Sener G Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn's disease PLoS One 16 e0260034 2021 10.1371/journal.pone.0260034 34788319
123 Fattinger SA Geiser P Samperio Ventayol P Di Martino ML Furter M Felmy B Bakkeren E Hausmann A Barthel-Scherrer M Gül E Epithelium-autonomous NAIP/NLRC4 prevents TNF-driven inflammatory destruction of the gut epithelial barrier in Salmonella-infected mice Mucosal Immunol 14 615 629 2021 10.1038/s41385-021-00381-y 33731826
124 Mizoguchi A Animal models of inflammatory bowel disease Prog Mol Biol Transl Sci 105 263 320 2012 10.1016/B978-0-12-394596-9.00009-3 22137435
125 Saleh M Trinchieri G Innate immune mechanisms of colitis and colitis-associated colorectal cancer Nat Rev Immunol 11 9 20 2011 10.1038/nri2891 21151034
126 Kiesler P Fuss IJ Strober W Experimental models of inflammatory bowel diseases Cell Mol Gastroenterol Hepatol 1 154 170 2015 10.1016/j.jcmgh.2015.01.006 26000334
127 Henderson LA Cron RQ Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: Diagnosis and management Paediatric drugs 22 29 44 2020 10.1007/s40272-019-00367-1 31732958
128 Bardet J Laverdure N Fusaro M Picard C Garnier L Viel S Collardeau-Frachon S De Guillebon JM Durieu I Casari-Thery C NLRC4 GOF mutations, a challenging diagnosis from neonatal age to adulthood J Clin Med 10 4369 2021 10.3390/jcm10194369 34640385
129 Volker-Touw CM de Koning HD Giltay JC de Kovel CGF van Kempen TS Oberndorff KMEJ Boes ML van Steensel MAM van Well GTJ Blokx WAM Erythematous nodes, urticarial rash and arthralgias in a large pedigree with NLRC4-related autoinflammatory disease, expansion of the phenotype Br J Dermatol 176 244 248 2017 10.1111/bjd.14757 27203668
130 Moghaddas F Zeng P Zhang Y Schützle H Brenner S Hofmann SR Berner R Zhao Y Lu B Chen X Autoinflammatory mutation in NLRC4 reveals a leucine-rich repeat (LRR)-LRR oligomerization interface J Allergy Clin Immunol 142 1956 1967.e6 2018 10.1016/j.jaci.2018.04.033 29778503
131 Trifiletti R Lachman HM Manusama O Zheng D Spalice A Chiurazzi P Schornagel A Serban AM van Wijck R Cunningham JL Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing Sci Rep 12 11106 2022 10.1038/s41598-022-15279-3 35773312
132 Eeckhout E Asaoka T Van Gorp H Demon D Girard-Guyonvarc'h C Andries V Vereecke L Gabay C Lamkanfi M van Loo G Wullaert A The autoinflammation-associated NLRC4V341A mutation increases microbiota-independent IL-18 production but does not recapitulate human autoinflammatory symptoms in mice Front Immunol 14 1272639 2023 10.3389/fimmu.2023.1272639 38090573
